Drug Trial Radar · NCT03997123
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
923
Actual
Start
Jun 25, 2019
Primary completion
Mar 16, 2026
Study completion Mar 16, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Conditions
- Triple Negative Breast Neoplasms
Interventions
CapivasertibDrug
400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
PaclitaxelDrug
80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
PlaceboDrug
Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: The time from date of randomisation to the date of death due to any cause up to approximately 42 months
Locations
260 sites in 30 countries. Site status is shown where the registry gives one.
Research Site
Whittier, California
Research Site
Whittier, California
Research Site
Fort Myers, Florida
Research Site
Miami, Florida
Research Site
St. Petersburg, Florida
Research Site
Tampa, Florida
Research Site
Chicago, Illinois
Research Site
Westwood, Kansas
Research Site
Silver Spring, Maryland
Research Site
Detroit, Michigan
Research Site
Nyack, New York
Research Site
Cincinnati, Ohio
Research Site
Columbus, Ohio
Research Site
Harrisburg, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Nashville, Tennessee
Research Site
Austin, Texas
Research Site
Fort Worth, Texas
Research Site
Houston, Texas
Research Site
San Antonio, Texas
Research Site
Fairfax, Virginia
Research Site
Buenos Aires, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
CABA, Argentina
Research Site
Ciudad Autonomade Buenos Aires, Argentina
Research Site
La Plata, Argentina
Research Site
Mar del Plata, Argentina
Research Site
Rosario, Argentina
Research Site
Barretos, Brazil
Research Site
Florianópolis, Brazil
Research Site
Goiânia, Brazil
Research Site
Londrina, Brazil
Research Site
Natal, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
São José do Rio Preto, Brazil
Showing 40 of 260 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.